Paper Details

  1. Home
  2. Paper Details

VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).

Author: AzaisI, BernardJ F, De GramontA, DoyenC, Euller-ZieglerL, GrosboisB, LaporteJ P, Le LoëtX, MichauxJ L, MineurP, MonconduitM, MénardJ F, PenyA M, PolletJ P, WetterwaldM

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the effectiveness of VAD (vincristine, doxorubicin, dexamethasone) and VMBCP (vincristine, BCNU, cyclophosphamide, melphalan and prednisone) as salvage treatments for multiple myeloma patients who had progressed on cyclophosphamide-prednisone therapy. Both regimens showed similar efficacy, and survival was significantly influenced by Karnofsky index and albumin levels.
Paper Details　
Original Abstract of the Article :
263 patients (median age 65+/-10 years) with multiple myeloma were treated with cyclophosphamide-prednisone. Out of this cohort, 103 patients had progressive disease and were randomly assigned to either VAD (vincristine, doxorubicin, dexamethasone; 50 cases) or VMBCP (vincristine, BCNU, cyclophospha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2141.1998.00997.x

データ提供：米国国立医学図書館（NLM）

VAD vs. VMBCP: A Desert Duel in Multiple Myeloma

[Multiple myeloma] is a challenging [hematological malignancy] with a need for effective treatment options. This study compares the efficacy of two chemotherapy regimens, [VAD (vincristine, doxorubicin, dexamethasone)] and [VMBCP (vincristine, BCNU, cyclophosphamide, melphalan and prednisone)], as [salvage treatment] for patients with [multiple myeloma] who had progressed or relapsed after initial treatment with [cyclophosphamide-prednisone]. The researchers conducted a [randomized trial] to evaluate the [survival] and [response rates] of the two regimens and found no significant difference in overall efficacy between the two.

Navigating the Terrain of Myeloma Treatment

This research offers valuable insights into the effectiveness of [VAD] and [VMBCP] as [salvage treatment] options for [multiple myeloma]. The authors' findings suggest that both regimens offer comparable efficacy in this setting. However, it is important to note that [prognostic factors] such as [Karnofsky index] and [albuminaemia] can significantly impact [survival]. The authors emphasize the need for individualizing treatment strategies to optimize patient outcomes.

The Desert Oasis of Myeloma Treatment

This research sheds light on the complex landscape of [multiple myeloma] treatment. While the authors found no significant difference in efficacy between [VAD] and [VMBCP], they emphasize the importance of considering individual patient factors, such as [prognostic indicators], when making treatment decisions. This research reminds us that the desert of [myeloma] treatment requires a careful and individualized approach to ensure the best possible outcomes for patients.

Dr. Camel's Conclusion

This research underscores the need for personalized treatment strategies in [multiple myeloma] and highlights the importance of considering [prognostic factors] to guide treatment decisions.

Date :
  1. Date Completed 1998-12-29
  2. Date Revised 2019-07-05
Further Info :

Pubmed ID

9827927

DOI: Digital Object Identifier

10.1046/j.1365-2141.1998.00997.x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.